Subscribe to our Newsletters !!
Anemones Sea have a striking beauty and the abilit
With reliance on data, analytical labs are challen
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Potassium cyanide is infamous in the world for the
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
One major driver of this rapid biopharma growth is the increasing demand for biologics – specifically for monoclonal antibodies, vaccines, and cell and gene therapies. Critical to this area of innovation is the biopharma analytics that, although often overlooked, are very sophisticated and fortify safety, efficacy and consistent quality of developed biologics. As such, they are the cornerstone of new-age drug development.
Biologics are also unique in that they are considerably larger than molecules that are synthesized in a lab. As biologics derive from a living system (biogenetics), they have associated structural complexities. This leads to variability, making thorough and extensive analytical testing imperative, particularly across the product development timeline.
Without robust analytics, ensuring the quality of biologics would be nearly impossible.
HPLC and UPLC are invaluable for the separation of biomolecules, quantitation, impurity profiling and characterization of the product of interest.
MS is the gold standard for the determination of the molecular weight, structure, and modifications of the constituents of a biological product, making it crucial for the identification and characterization of proteins in biologics.
Cell-based assays and Enzyme-Linked Immunosorbent Assays (ELISA) are the primary methods for determination of biological activity and overall therapeutic efficacy, and potency of biologics.
Electrophoresis methods, including SDS-PAGE, and capillary electrophoresis (CE), are used for the evaluation of proteins for parameters such as size, charge, and purity/profile, making it valuable for quality control.
Analytical methods used in the biopharma industry apply to multiple stages throughout the lifecycle of a product:
Continuous oversight of analytical methods ensures adherence to the applicable standards set for the biopharma products.
The U.S. Food and Drug Administration and the European Medicines Agency are global regulatory authorities that provide standards for biopharma products. Standards, such as the ICH Q2 (Validation of Analytical Procedures), provide guidance to ensure standards of safety and reliability.
Without accurate and reproducible methods of analysis, products remain unregulated, and the market loses confidence.
The biopharma industry is in a state of transformation with the introduction of automation, artificial intelligence (AI), and data analytics in the laboratories.
The introduction of such concepts is promising to improve precision and reliability in data generation and to improve timelines in the development of biopharma products.
The challenges noted will require standardized practices, a reasonable amount of time, and adequate financial resources to overcome.
The future of biopharma methodical analysis is about integration and intelligence. With mass spectrometry and multi-attributes methods (MAM) and real-time release testing (RTRT), there is a greater shift toward a more data-centric and streamlined method of testing. The analytical frameworks that support biologics will evolve concurrently with biopharma innovation. This ensures that progress is matched with diligence and compliance.
Biopharma analytical methods provide a veil of support for the progress of modern biologics. Biopharma methods of analysis are simply the starting point for the evolution of biologics therapeutics. They provide the scientific support for therapeutics to be safe, effective, and to the highest quality.
Defensively, these methods must evolve to provide the analytical support that will be required of the rapidly innovating biopharma therapeutics.
